A comprehensive view of Samsung Bioepis Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Samsung Bioepis settles patent litigation with J&J, paving way for US sales of plaque psoriasis treatment SB17 from February 22, 2025, upon FDA approval; Sandoz to handle commercialization
Published: December 01, 2023 by PharmaShots
GlobalData expects Samsung Bioepis and Organon's SB5 to be leading Humira biosimilar for chronic plaque psoriasis, with US$832M in global sales by 2029; SB5 is available in prefilled syringe and prefilled autoinjector, making it easy to self-administer
Published: September 07, 2023 by Express Pharma (India)

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count